natgillin/translations-raw huggingface dataset:
This suggests that the compounds may lack the dopaminergic side effects produced by tetrabenazine. 
To sugerira da spojevima mogu nedostajati dopaminergična nuz-djelovanja izazvana tetrabenazinom.
The monoclonal antibody or antigen binding fragment thereof of claim 1, which binds to at least four CC chemokines selected from the group consisting of CCL3/MIP-1a, CCL4/MIP-1B, CCL5/RANTES, and CCL23/MPIF-1, and which does not bind to CCL2/MCP-1. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da veže na najmanje četiri CC kemokina odabranih iz skupine koja se sastoji od CCL3/MIP-1a, CCL4/MIP-1B, CCL5/RANTES, i CCL23/MPIF-1, i koji se ne vežu na CCL2/MCP-1.
The method of claim 8, further comprising recrystallizing the purified pirfenidone by dissolving at least a portion of the purified pirfenidone in an acidic aqueous solution, optionally comprising hydrochloric acid, at a temperature of at least 35°C, to form a pirfenidone solution; adding a basic solution, optionally comprising sodium hydroxide, to the pirfenidone solution until the pH is at least about 11; and cooling the basic pirfenidone solution to a temperature below about 20°C, optionally below 10°C, to form recrystallized pirfenidone. 
Postupak prema zahtjevu 8, naznačen time da dodatno sadrži rekristalizaciju pročišćenog pirfenidona pomoću: otapanja barem dijela pročišćenog pirfenidona u kiseloj vodenoj otopim, koja proizvoljno sadrži klorovodičnu kiselinu, na temperaturi od barem 35"C, da se dobije otopina pirfenidona; dodavanja bazične otopine, koja proizvoljno sadrži natrijev hidroksid, u otopinu pirfenidona sve do dobivanja pH barem od oko 11; te hlađenja bazične otopine pirfenidona na temperaturu ispod oko 20*C, proizvoljno ispod 10%C, da se dobije rekristalizirani pirfenidon.
The pharmaceutical composition of claim 7, further comprising an additional therapeutic agent. 
Farmaceutski sastav prema zahtjevu 7, naznačen time, da nadalje obuhvaća dodatno terapeutsko sredstvo.
The residue was purified by flash chromatography (SiO2) using 25% ethyl acetate-hexanes to give the desired product as a white solid. 
Ostatak se pročisti svjetlosnom kromatografijom (9102) uporabom 25% etil acetat-heksana da bi se dobio željeni spoj kao bijela krutina.
An isolated antibody for use in treating cancer according to claim 9 wherein said cancer is hematological cancer and is selected from the group consisting of multiple myeloma, chronic lymphoblastic leukemia, chronic lymphocytic leukemia, plasma cell leukemia, acute myeloid leukemia, chronic myeloid leukemia, B-cell lymphoma, and Burkitt's lymphoma. 
Izolirano protutijelo u skladu s patentnim zahtjevom 1, naznačeno time da je navedeni hematološki karcinom odabran iz skupine koju čine multipli mijelom, kronična limfoblastična leukemija, kronična limfocitna leukemija, leukemija stanica plazme, akutna mijeloidna leukemija, kronična mijeloidna leukemija, limfom B stanica 1 Burkittov limfom.
recovering an eluate enriched in an anti-Hib immunoglobulin, anti-Hbs immunoglobulin, anti-PV1 immunoglobulin, anti-HAV immunoglobulin, anti-CMV immunoglobulin, anti-tetanus immunoglobulin, anti-parvo B19 immunoglobulin, anti-diphtheriae immunoglobulin, or a combination thereof. 
obnavljanje eluata obogaćenog anti-Hib imunoglobulinom, anti-Hbs imunoglobulinom, anti-PV1 imunoglobulinom, anti-HAV imunoglobulinom, anti-CMV imunoglobulinom, anti-tetanus imunoglobulinom, anti-parvo B19 imunoglobulinom, ili anti-difterija imunoglobulinom, ili njihovom kombinacijom.
Preparation of the Fraction of Microparticles. 
Broj objave europskog patenta:
The system may comprise a wastewater delivery pipe having two branches in the pumping chamber. 
Sustav sukladno patentnom zahtjevu 8 nadalje obuhvaća cijev (11) za isporuku otpadne vode koja ima dvije grane u komori za pumpanje.
The composition according to claim 6 wherein the gamma-tocopherol is present in an amount of 100 mg to 3000 mg. 
Pripravak u skladu sa zahtjevom 6 naznačen time da je gama-tokoferol prisutan u količini od 100 mg do 3000 mg.
Use according to claim 17, characterized in that following addition of said 2-((1-methylpropyl)amino)ethanol to said suspension, the suspension is passed through a passage having a suspension throughput regulated as a function of the suspension conductivity. 
Uporaba u skladu s patentnim zahtjevom 17, karakterizirana na način da nakon dodavanja navedenog 2-((1- metilpropil)amino)etanola u navedenu otopinu, otopina prolazi kroz prolaz koji ima protok otopine reguliran kao funkciju vodljivosti otopine.
The method of claim 2, wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Crohn's disease, Sjogren's syndrome, Grave's disease, type I diabetes mellitus, psoriasis, immune thrombocytopenic purpura, pemphigus, idiopathic inflammatory myopathy, myasthenis gravis, and Waldenstorm's macroglobinemia. 
Humanizirani CD37-specifični vezni protein iz bilo kojeg od patentnih zahtjeva 1 do 8, ili sastav iz patentnog zahtjeva 10, za uporabu u liječenju autoimune bolesti, pri čemu je autoimuna bolest reumatoidni artritis, multipla skleroza, sustavni eritemski lupus, Chronova bolest, Sjogrenov sindrom, Gravesova bolest, šećerna bolest tipa I, psorijaza, imuna trombocitopenična purpura, pemfigus, idiopatska upalna miopatija, miastenija gravis, ili Waldenstromova makroglobulinemija.
Of interest also is the (1R)-enantiomer of cis-N-methyl-4-(3,4-dichlorophenyl)-1.2,3,4-tetrahydro-1-naphthalenamine, which exhibits surprisingly good norepinephrine and serotonin uptake blocking activity. 
Također je interesantan (1F)-enantiomer cis-N-metil-4-(3,4-diklorofenil)-1,2,3,4-tetrahidro-1-naftalinamina, koji pokazuje neočekivano dobru aktivnost za blokiranje potrošnje norepinefrina i serotonina.
A method as claimed in claim 7, wherein the outlet is provided with a flow area restriction for creating the pressure drop. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time što se na izlazu ograniči zonu tečenja kako bi došlo do pada tlaka.
A genetically modified cell comprising a genomic modification made by a zinc finger nuclease (ZFN) or TAL-effector domain nuclease (TALEN), wherein the genomic modification is within any one of the nuclease target sequences of SEQ ID NOs: 4-80, 143-184, 232-251 and 276 of an endogenous BCL11a enhancer sequence, and further wherein the genomic modification is an insertion and/or deletion. 
Genetski modificirana stanica koja sadrži genomsku modifikaciju nastalu djelovanjem nukleaze sa cinkanim prstićima (ZFN) ili nukleaze sa efektorskom domenom tipa TAL (TALEN), pri čemu je genomska modifikacija unutar bilo koje od nukleaznih ciljnih sekvenci u SEQ ID NO: 4-80, 143-184, 232-251 1 276 endogene sekvence pojačivača BCLI 1a i, dalje, pri čemu je genomska modifikacija tipa insercije i/ili delecije.
Figure 13 shows one embodiment of the ring 1103 that may be coupled to the mouth of the container 1100. 
Slika 13 prikazuje jedno ostvarenje obruča 1103 koji može biti spojen za vrh posude 1100.
A vaginal suppository according to claim 5, wherein the content of lactic acid and neutralizing substance is such that the pH lies within the range of 3.5 to 4.5. 
Vaginaleta sukladno patentnom zahtjevu 4, pri tome je sadržaj mliječne kiseline i neutralizirajuće tvari takav da je pH unutar opsega od 3.5 do 4.5.
The preformed air-tight covering 3 can be manufactured in the following manner. 
Prethodno oblikovan neprodušan pokrov 3 može se izraditi na slijedeći način.
Y is hydrogen or an optionally substituted straight or branched (C1-C3) alkyl; and R′ and R″ are independently hydrogen or an optionally further substituted straight or branched (C1-C6) alkyl, or taken together with the carbon atom to which they are bonded R′ and R″ may form an optionally substituted (C3-C8) cycloalkyl; 
Y je vodik ili izborno supstituirani nerazgranati ili razgranati (C;-C3) alkil; i1R'iR" su neovisno vodik ili izborno dodatno supstituiran nerazgranati ili razgranati (C;-Cg) alkil, ili uzeti zajedno s atomom ugljika na kojeg su vezani R'i R" mogu tvoriti izborno supstituirani (C3-Cg) cikloalkil;
According to the invention, part of the sucrose is replaced by a bulking fibre composition that comprises mainly so-called prebiotic fibres. 
Prema ovom izumu, dio saharoze zamjenjuje se sastavinom vlakana koja povećavaju masu i koja sadržava pretežno tzv. prebiotička vlakna.
In certain embodiments, the bacterial strain for use in the invention has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to the 16s rRNA sequence of a bacterial strain of Blautia hydrogenotrophica . 
Sastav za upotrebu prema zahtjevima 1-6, gdje bakterijski soj ima 16s rRNK sekvencu koja je najmanje 95%, 96%, 97%, 98%, 99%, 99.5% ili 99.9% identična sa 16s rTRNK sekvencom bakterijskog soja Blautia hydrogenotrophica.
Interpretation of DLS data can be complicated by the presence of slowly-varying components, such as dust particles or mixing phenomena. 
Interpretacija podataka DLS može se komplicirati prisutnošću polako varirajućih komponenata, kao što su čestice prašine ili fenomeni miješanja.
The conjugate according to claim 6, wherein said conjugate consists of the amino acid sequence set forth in SEQ ID NO: 58, or SEQ IQ NO: 61. 
Konjugat u skladu s patentnim zahtjevom 6, pri čemu se navedeni konjugat sastoji od aminokiselinskog slijeda predvodnika iz SEQ ID NO: 58, ili SEQ ID NO: 61,
The host cell of claim 38, wherein the host cell is a eukaryotic cell. A method for producing a polypeptide comprising the amino acid sequence encoded by the PES11, the method comprising culturing a host cell that comprises the vector of claim 37 in a culture medium. The method of claim 41, wherein the method further comprises recovering the polypeptide from the host cell or the culture medium. 
eukariotska stanica, pri čemu eukariotska stanica je stanica Expi293F. Postupak proizvodnje polipeptida, naznačen time, da obuhvaća uzgoj stanice domaćina koja sadrži komplet vektora prema patentnom zahtjevu 23, u podlozi za uzgoj kultura, preferirano s time, da postupak nadalje obuhvaća izdvajanje polipeptida iz stanice domaćina ili podloge za uzgoj kultura.
Additionally, the yield of the reaction is 82% for the risedronic acid and 67% for the monosodium salt thereof if proper pH and drying conditions are ensured. 
K tome, prinos ovog postupka je 82% za risedronsku kiselinu i 67% za njenu mononatrijevu sol, ukoliko se osiguraju odgovarajući uvjeti pH i sušenja.
in admixture with a pharmaceutically acceptable carrier therefor. The pharmaceutical composition of claim 13 further comprising a molecule selected from the group consisting of a reporter molecule, a water soluble polymer, an antibody Fc region, and a cytotoxic agent. 
Farmaceutska smjesa iz zahtjeva 7, naznačena time, što sadrži još i molekulu koja se bira iz grupe koja se sastoji od reporterske molekule, polimera topljivog u vodi, Fc regije antitijela i citotoksičnog sredstva.
The molecular weight of said substances typically does not exceed 500, preferably it does not exceed 400, more preferably it does not exceed 350. 
Molekulska masa spomenutih tvari tipično ne prelazi 500, poželjno ne prelazi 400, poželjnije ne prelazi 350. HR P20070273 T3
In still another embodiment of the present disclosure, the binding buffer is water optionally along with polyols or non-polyols. In still another embodiment of the present disclosure, the polyol comprises water soluble polyol compounds selected from a group consisting of Poly-ethylene glycol, glycerol, Poly-propylene glycol, ethylene glycol and propylene glycol. In still another embodiment of the present disclosure, the non-polyol comprises alcohols consisting of methanol, ethanol, propanol or any water-soluble liquid with a functional group of acid, amine, alcohol, phenol, amide or ester as one of the functional groups; or any combination thereof. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je navedeni pufer za vezanje voda, uz izborno poliole ili nepoliole, gdje navedeni poliol izborno sadrži poliolne spojeve topljive u vodi, koje se bira iz skupine koju čine polietilen-glikol, glicerol, polipropilen-glikol, etilen-glikol i propilen-glikol; te gdje navedeni nepoliol sadrži alkohole, koje se bira iz skupine koju čine metanol, etanol, propanol ili bilo koja tekućina topljiva u vodi s funkcionalnom skupinom koju se bira iz skupine koju čine kiselina, amin, alkohol, fenol, amid ili ester kao jedna od funkcionalnih skupina; ili bilo koja njihova kombinacija.
is C1-C4 alkyl (optionally substituted with 1, 2 or 3 fluorine atoms), C1-C4 alkoxy (optionally substituted with 1, 2 or 3-fluorine atoms) or phenyl (optionally substituted with 1, 2 or 3 fluorine atoms); and R5 is H or F; or a pharmaceutically acceptable salt thereof. 
R? je Ci-Ca alkil (izborno supstituiran s 1, 2 ili 3 atoma fluora), Ci-Ca alkoksi (izborno supstituiran s 1, 2 ili 3 atoma fluora) ili fenil (izborno supstituiran s 1, 2 ili 3 atoma fluora); i R'jeHiliF; ili njegova farmaceutski prihvatljiva sol.
The communication cable splice box according to claim 14, wherein the first fixture is mechanically jointed with the supporting portion. The communication cable splice box according to claim 14, wherein the supporting portion is connected to the first fixture, and the supporting portion is fixed to the communication cable splice box. 
Spojna kutija za komunikacijski kabel (40, 50, 60, 80) prema zahtjevu 8, naznačena time da je nosivi dio (93, 97) spojen sa prvim držačem (93A, 98), te je nosivi dio (93, 97) učvršćen na spojnu kutiju za komunikacijski kabel (40,
As can be seen from Fig. 8, especially in case the sealing member 8 covers a portion of the side walls 7 of the capsule 1, the annular front surface of the bell member 9 can be uneven, e.g. by providing grooves 21 or other corrugations which, act as air inlet passage for feeding air. 
Kao što se može vidjeti iz slike 8, naročito u slučaju da element za nepropusno zatvaranje 8 prekriva dio bočnih stijenki 7 čahure 1, prednja kružna površina zvonastog elementa 9 može biti neravna, na primjer, stavljanjem utora 21 ili drugih hrapavosti koje djeluju kao prolaz za zrak koji ulazi kod dovođenja zraka.
By means of said device, the process according to the invention can be realized in a particularly simple and fast manner in order to achieve the advantages which are discussed above. 
Pomoću navedenog uređaja može se postupak koji je u skladu s ovim izumom ostvariti na naročito jednostavan i brz način, da bi se pri tome postigle prednosti o kojima se gore raspravlja.
the proportion of the inorganic salt is 1 to 20 parts by weight, the proportion of the sulfonate is 0.1 to 20 parts by weight. 
omjer herbicidnog spoja sulfoniluree ili njegove soli iznosi od 0 do 50 masenih udjela, udio anorganske soli je od 1 do 20 masenog udjela, udio sulfonata je od 0,1 do 20 masenog udjela.
A use according to claim 3 wherein said antimicrobial agent and said chelating agent are administered to said plant: 
Uporaba prema patentnom zahtjevu 3 naznačena time što se navedeno antimikrobno sredstvo i navedeno helatirajuće sredstvo primjenjuju na navedenu biljku:
The dosage regimen utilizing the compounds of the present invention is selected by one of ordinary skill in the medical or veterinary arts considering various factors, such as without limitation, the species, age, weight, sex, medical condition of the recipient, the severity of the condition to be treated, the route of administration, the level of metabolic and excretory function of the recipient, the dosage form employed or the particular compound and salt thereof employed. 
+ VL dt £ različite čimbenike, poput, bez ograničavanja, vrste, dobi, težine, spola, medicinskog stanja primatelja, težini stanja koje se liječi, načinu primjene, razini metaboličkih i ekskrecijskih funkcija primatelja, upotrijebljenom obliku doziranja ili o upotrijebljenom pojedinom spoju i njegovoj soli.
The crude solid was recystallized from CH2Cl2 (30ml) and hexanes (500 mL) to give the title compound, 3,5-dichloro-4,5-bis(4-chlorophenyl)pyridazine as beige solid (5.0 gm, 45% for the 2 steps). 
Sirova krutina je rekristalizirana iz CH>CL (30 mL) i heksana (500 mL) pri čemu se dobiva spoj iz naslova, 3,5-dikloro-4,5-bis(4-klorofenil)piridazin kao bež krutina (5.0 mg, 45% za dva koraka).
Another object of the invention is to provide a method for manufacturing a therapeutic hosiery item according to the invention with a circular hosiery knitting machine. 
Daljnji predmet izuma je osigurati postupak za proizvodnju terapeutske čarape prema izumu s kružnim strojem za pletenje čarapa.
Dihydrospiro-[cycloalkylamine]-pyrimidone derivates represented by formula (I) or salts thereof, solvates thereof or hydrates, wherein X, Y, R1, R2, R3, O, n, p, q, are as defined hereinabove and R4 represents a hydrogen atom, a C1-4alkoyl carbonyl group, C1-6 alkyl group optionally substituted by 1 to 4substituents selected frona halogen atom, a hydroxyl group or a C1-4 alkoxy group; represent another object of the invention. 
Dihidrospiro[cikloalkilamin/pirimidonski derivati, prikazani formulom (1), ili njihove soli, njihovi solvati ili hidrati, gdje X, Y, RI, R2, R3, 0, 1, p, q su defininirani kao gore, a R4 predstavlja atom vodika, Ci. alkoksikarbonilnu skupinu, Cig alkilnu skupinu, izborno supstituiranu s 1 do 4 supstituenta, koje se bira između atoma halogena, hidroksilne skupine ili C;.4 alkoksi skupine; te predstavljaju joše jedan cilj ovog izuma.
The compound according to claim 6 or a pharmacologically acceptable salt thereof, wherein in the formula (I), Ar1 is a group selected from the group consisting of B1), B2), B6a), B9a), and B9b): 
< Spoj u skladu sa patentnim zahtjevom 6 ili njegova farmakološki prihvatljiva sol, ili njegov solvat ili hidrat, gdje izraz "po izboru ima supstituent(e)" ima značenje definirano u patentnom zahtjevu 1, i gdje u formuli (1), Ar' je grupa odabrana iz grupe koja se sastoji od B1), B2), B6a), B9a), i B9b):
The method according to claim 4, further comprising forcing metal contact plates into conductive engagement with respective ones of the plurality of wires. 
Metoda u skladu sa zahtjevom 9, naznačena time da nadalje obuhvaća prisiljavanje metalnih kontaktnih ploča na provodljivo spajanje s odgovarajućim mnoštvom žica (16).
a compound represented by: 
(ii) spoj predstavljen s:
The inner part comprises a non-metallic material. 
Unutarnji dio sadržava ne-metalni materijal.
The final coating had high gloss, good adhesion, no yellowing, and pencile hardness H. These properties were comparable to the properties of a coating prepared using volatile organic solvents instead of FAME. REFERENCE 
Krajnja prevlaka imala je visok sjaj, dobru adheziju, nije požutila i mala je tvrdoću mjerenu s iglom H. Ta svojstva se mogu usporediti sa svojstvima prevlake izrađene upotrebom hlapljivog organskog otapala umjesto FAME-a.
a 5-6 membered heteroaryl ring having 1-2 nitrogen atoms; 
(ii) - 5-6-eročlani heteroarilni prsten s 1-2 atoma dušika;
Detailed description of invention 
(54) Naziv izuma:
a stack of dielectric layers and electrode layers arranged one above another, wherein electrode layers of identical electrical polarity are jointly contacted to an external contact arranged at a side face of the stack; and 
- - elektrodni slojevi iste električne polarnosti su međusobno kontaktno povezani s vanjskim kontaktom (5a, 5b) smješteni na bočnoj strani sloga, te gdje
which compound is further reacted with Et3SiH and trifluoro acetic acid followed by reaction with an acid to remove the N-piperidine protecting group and optionally to obtain a desired acid addition salt. 
BOR a taj spoj dalje reagira s EGSiH i trifluor octenom kiselinom, nakon čega slijedi reakcija s kiselinom da se ukloni N- piperidin zaštitna skupina i po izboru da se dobije željena kisela adicijska sol.
The conjugate according to claim 1 or 2, wherein the conjugate has anti-obesity effects. 
Konjugat prema bilo kojem od zahtjeva 1 do 6, naznačen time da konjugat ima učinak protiv pretilosti.
In another embodiment, in formula (VI), R41 is selected from the group consisting of —H, methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy, ethoxy, propoxy, and cyclopropoxy. 
Spoj prema zahtjevu 19, pri čemu je R4, izabran iz skupine koju čine -H, metil, etil, propil, izopropil, ciklopropil, metoksi, etoksi, propoksi 1 ciklopropoksi.
in which R1A and R2 are each as defined above, reacting the compound of formula (X) in an inert solvent, in the presence of a suitable catalyst and a suitable base, with a compound of the formula (XI) 
(X) gdje R" i R* su svaki kako je gore definirano, te ovo nakon toga reagira u inertnom otapalu, u prisutnosti prikladnog katalizatora i odgovarajuće baze, sa spojem s formulom (XI)
Moreover, the risk of delicate tissue being damaged is considerably limited. 
Osim toga, opasnost da se osjetljivo tkivo ošteti je znatno ograničena.
The shoe as claimed in claim 1, wherein a connection member combines a lower edge of the side panel, a lower edge of the vamp and two sides of the insole. 
Cipela prema patentnom zahtjevu 1, kod koje je veznim elementom (5) spojen donji brid bočne oplate (2), donji brid gornje kože (10) 1 obje strane unutrašnjeg dona (4).
The sealing material is pressed against the cooperating enclosing member to form a flow resistance which is effective to enable pressure inside the capsule sufficient to assist in the opening of the outlet face. BRIEF DESCRIPTION OF THE DRAWINGS 
Materijal za brtvljenje se pritišće na odgovarajući element koji obuhvaća čahuru da bi se tako stvorio otpor za protjecanje, koji otpor djeluje tako da omogući tlaku unutar čahure da bude dovoljno visok kako bi pomogao otvaranje izlazne plohe.
CDRL2 comprises the sequence of SEQ ID NO: 41 or a variant thereof; and CDRL3 comprises the sequence of SEQ ID NO: 46 or a variant thereof; wherein each variant comprises up to five conservatively modified amino acid substitutions; 
CDRL2 sadrži sekvencu prema SEQ ID NO: 41 ili njenu varijantu; i CDRL3 sadrži sekvencu prema SEQ ID NO: 46 ili njenu varijantu; gdje svaka varijanta sadrži do jednu konzervativno modificiranu aminokiselinsku supstituciju; i
The method of claim 1 wherein the contacting step occurs when the composition is consumed by a feline present in said environment. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što do koraka stavljanja u kontakt dolazi kada pripravak konzumira mačka koja se nalazi u navedenom okolišu.
the first variant Fc-region polypeptide is derived from a first parent IgG class Fc-region polypeptide and the second variant Fc-region polypeptide is derived from a second parent IgG class Fc-region polypeptide, whereby the first parent IgG class Fc-region polypeptide is identical to or different from the second parent IgG class Fc-region polypeptide, and 
polipeptid prve varijante Fc regije dobiva iz matičnog polipeptida prve varijante Fc regije klase IgG, a polipeptid druge varijante Fc regije dobiva iz matičnog polipeptida druge varijante Fc regije klase IgG, pri čemu je matični polipeptid prve varijante Fc regije klase IgG isti kao ili različit od matičnog polipeptida druge varijante Fc regije klase IgG, i
Packaging unit (2, 62, 94) comprising: 
Jedinica za pakiranje (2, 62, 94) koja sadrži:
comprises a mature type I elastase protein having an activity of 20 to 50 U/mg of protein as quantified using a colorimetric N-succinyl-Ala-Ala-Ala-pNitroanilide (SLAP) hydrolysis assay, wherein the upper limit of trypsin in said pharmaceutical composition is less than 25 ng of trypsin per 1 mg of mature type I elastase protein, and wherein: 
(a) obuhvaća zreli tip I protein elastaze koji ima aktivnost od 20 do 50 U/mg proteina kao kvantificiranog koristeći kolorimetrijski N-sukcinil-Ala-Ala-Ala-pNitroanilid (SLAP) hidrolizacijski test, pri čemu je gornja granica tripsina u spomenutom farmaceutskom sastavu manja od 25 ng tripsina po 1 mg zrelog tipa I protein elastaze, i pri čemu:
Stereoisomeric forms define all the possible isomeric forms that the compounds of formula (I) may possess. 
Stereoizmerni oblici definiraju sve moguće izomerne oblike koje sojevi formule (I) mogu imati.